Warning: The NCBI web site requires JavaScript to function. more...
Inhibitory short synthetic oligodeoxynucleotides and lupus.
Liu Z, Davidson A.
Arthritis Res Ther. 2009;11(3):116. Epub 2009 Jun 26.
Related citations
DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRL-Fas(lpr/lpr) mice in vivo.
Lenert P, Yasuda K, Busconi L, Nelson P, Fleenor C, Ratnabalasuriar RS, Nagy PL, Ashman RF, Rifkin IR, Marshak-Rothstein A.
Arthritis Res Ther. 2009;11(3):R79. Epub 2009 May 28.
Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus.
Lenert P.
Clin Exp Immunol. 2010 Aug;161(2):208-22. Epub 2010 May 7. Review.
Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process.
Papadimitraki ED, Choulaki C, Koutala E, Bertsias G, Tsatsanis C, Gergianaki I, Raptopoulou A, Kritikos HD, Mamalaki C, Sidiropoulos P, Boumpas DT.
Arthritis Rheum. 2006 Nov;54(11):3601-11.
Development of TLR inhibitors for the treatment of autoimmune diseases.
Barrat FJ, Coffman RL.
Immunol Rev. 2008 Jun;223:271-83. Review.
Targeting Toll-like receptors for treatment of SLE.
Horton CG, Pan ZJ, Farris AD.
Mediators Inflamm. 2010;2010. pii: 498980. Epub 2010 Sep 19. Review.
The role of toll-like receptors in systemic lupus erythematosus.
Rahman AH, Eisenberg RA.
Springer Semin Immunopathol. 2006 Oct;28(2):131-43. Epub 2006 Sep 19. Review.
Type I interferon receptor controls B-cell expression of nucleic acid-sensing Toll-like receptors and autoantibody production in a murine model of lupus.
Thibault DL, Graham KL, Lee LY, Balboni I, Hertzog PJ, Utz PJ.
Arthritis Res Ther. 2009;11(4):R112. Epub 2009 Jul 22.
B-cell receptor for antigen modulates B-cell responses to complex TLR9 agonists and antagonists: implications for systemic lupus erythematosus.
Goeken JA, Layer T, Fleenor S, Laccheo M, Lenert P.
Lupus. 2010 Oct;19(11):1290-301. Epub 2010 Jul 6.
TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production.
Lenert P, Brummel R, Field EH, Ashman RF.
J Clin Immunol. 2005 Jan;25(1):29-40.
High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus.
Urbonaviciute V, Voll RE.
J Intern Med. 2011 Oct;270(4):309-18. doi: 10.1111/j.1365-2796.2011.02432.x.
Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors.
Christensen SR, Shlomchik MJ.
Semin Immunol. 2007 Feb;19(1):11-23. Epub 2007 Feb 2. Review.
Engagement of the B cell receptor for antigen differentially affects B cell responses to Toll-like receptor-7 agonists and antagonists in BXSB mice.
Layer T, Steele A, Goeken JA, Fleenor S, Lenert P.
Clin Exp Immunol. 2011 Mar;163(3):392-403. doi: 10.1111/j.1365-2249.2010.04307.x. Epub 2011 Jan 14.
[TLR function in autoimmunological processes].
Klonowska-Szymczyk A, Wolska A, Robak E.
Postepy Hig Med Dosw (Online). 2009 Jul 20;63:331-9. Review. Polish.
Activation profile of Toll-like receptors of peripheral blood lymphocytes in patients with systemic lupus erythematosus.
Wong CK, Wong PT, Tam LS, Li EK, Chen DP, Lam CW.
Clin Exp Immunol. 2010 Jan;159(1):11-22. Epub 2009 Oct 16.
Role for toll-like receptors in autoimmune disease: the example of systemic lupus erythematosus.
Richez C, Blanco P, Rifkin I, Moreau JF, Schaeverbeke T.
Joint Bone Spine. 2011 Mar;78(2):124-30. Epub 2010 Oct 18. Review.
TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus.
Guiducci C, Gong M, Xu Z, Gill M, Chaussabel D, Meeker T, Chan JH, Wright T, Punaro M, Bolland S, Soumelis V, Banchereau J, Coffman RL, Pascual V, Barrat FJ.
Nature. 2010 Jun 17;465(7300):937-41.
Regulatory T cells and systemic lupus erythematosus.
Mudd PA, Teague BN, Farris AD.
Scand J Immunol. 2006 Sep;64(3):211-8. Review.
Toll-like receptor ligands directly promote activated CD4+ T cell survival.
Gelman AE, Zhang J, Choi Y, Turka LA.
J Immunol. 2004 May 15;172(10):6065-73.
Treatment with a toll-like receptor inhibitory GpG oligonucleotide delays and attenuates lupus nephritis in NZB/W mice.
Graham KL, Lee LY, Higgins JP, Steinman L, Utz PJ, Ho PP.
Autoimmunity. 2010 Mar;43(2):140-55.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on